A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3020-3020 ◽  
Author(s):  
A. J. Wagner ◽  
J. C. Bendell ◽  
S. Dolly ◽  
J. A. Morgan ◽  
J. A. Ware ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Mtor Inhibitor ◽  
Advanced Solid Tumors

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

2020 ◽  
Vol 38 (6) ◽  
pp. 1755-1762 ◽  
Author(s):  
Mojun Zhu ◽  
Julian R. Molina ◽  
Grace K. Dy ◽  
Gary A. Croghan ◽  
Yingwei Qi ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Mtor Inhibitor ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors

scholarly journals Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors

2011 ◽  
Vol 69 (4) ◽  
pp. 1099-1105 ◽  
Author(s):  
Yoshitaka Seki ◽  
Noboru Yamamoto ◽  
Yosuke Tamura ◽  
Yasushi Goto ◽  
Takashi Shibata ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Mtor Inhibitor ◽  
Japanese Patients ◽  
Advanced Solid Tumors

A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3008-3008 ◽  
Author(s):  
S. Di Cosimo ◽  
J. C. Bendell ◽  
A. Cervantes-Ruiperez ◽  
D. Roda ◽  
L. Prudkin ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Mtor Inhibitor ◽  
Advanced Solid Tumors
Sign in / Sign up

Export Citation Format

Share Document